期刊文献+

1999年~2002年6城市医院抗肿瘤药物用药变化及趋势分析 被引量:2

Changes of the Usage of Antitumor Drugs and Analysis of the Tendency in the Hospitals of 6 Cities During 1999-2002
下载PDF
导出
摘要 目的分析6城市150家医院抗肿瘤药物用药的现状和趋势。方法:统计6城市150家医院抗肿瘤药物用药的金额、生产企业等,分析临床用药情况。结果:抗肿瘤用药金额2002年比1999年、2000年和2001年分别增加118.85%、74.40%和32.15%。结论:抗肿瘤药物在医院占有重要地位,且逐年快速增长(年均增长率为29.80%),抗肿瘤植物药、单抗药物和基因疗法将成为今后抗肿瘤药物治疗的主要趋势。 OBJECTIVE: To analyze the current status and the tendency for using antitumor drugs in 150 hospitals of 6 cities. METHODS: By counting sum of money of antitumor drugs and manufacturers in 150 hospitals of 6 cities, to analyze the status of clinical drug usage. RESULTS: Sum of money of antitumor drugs in 2002 respectively increased by 118.85%, 74.4% and 32.15% than that in 1999, 2000 and 2001. CONCLUSION: Antitumor drugs play an important part in the hospitals and increase quickly with years (the average annual incremental rate is 29.80%). Antitumor plant amedica, simple antitumor drugs and gene therapy will become main tendency for antitumor drug therapy in the future.
作者 黄萍 陈庆宪
出处 《中国医院用药评价与分析》 2004年第1期23-26,共4页 Evaluation and Analysis of Drug-use in Hospitals of China
关键词 1999年-2002年 医院 抗肿瘤药物 用药变化 癌症 antitumor drugs analysis of drug usage tendency prediction
  • 相关文献

参考文献2

二级参考文献16

  • 1胡发明.奥沙利铂的不良反应和安全性[J].国外医药合成药·生化药·制剂分册,1999,20(3):184-185.
  • 2Richard H, Wilson, Tanya Lehky, et al.Acute Oxaliplatin-Induced Peripheral Nerve Hyperexcitability[J] .J Clin Oncol,2002,20(7):1767 - 1774.
  • 3Adelsberger H,Quasthoff S,Grosskreutz J,et al.The chemotherapeutic oxaliplatin alters voltage-gated Na(+)channel kinetics on rat sensory neurons[J].Eur J Pharmacol,2000,406(1):25-32
  • 4Sarah Taieb, Louis Descos, Gilles Freyer, et al. Lhermitte sign and urinary retention-atypical presentation of oxaliplatin neurotoxicity in four patients[J]. Cancer, 2002,94(9) : 2434 - 2440.
  • 5Misset JL. Oxaliplatin in practice [ J ] . Br J Cancer, 1998, 77(Suppl 4):S4- S7.
  • 6Graham MA, Lockwood GF, Greenslade D, et al. Clinical pharmacokinetics of oxaliplatin; a critical review[ J ] . Clin Cancer Res ,2000,6(4) : 1205 - 1218.
  • 7Levi F, Metzger G, Massari C, et al. Oxaliplatin: pharmacokinetics and chronopharmacological aspeets[J]. Clin Pharmacokinet,2000,38(1) : 1 - 21.
  • 8Luo FR, Wyrick SD, Charley SG. Biotransformations of oxaliplatin in rat blood in vitro[J] .J Biochem Mol Toxicol ,1999 ,13(3-4):159- 169.
  • 9Gamelin E, LeBouil A, Boisdron-celle M, et al. Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluomuracil in colorectal cancer patients[J]. Clin Cancer Res, 1997,3(6) :891 - 899.
  • 10Raymond E, Chaney SG, Taamma A, et al. Oxaliplatin: a review of preclinical and clinical studies [ J ]. Ann Oncol, 1998,9 ( 10 ) :1053- 1071.

共引文献86

同被引文献10

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部